Trial Profile
A Phase II Efficacy And Safety Study Intravenous Edotecarin In Patients With Advanced Gastric Cancer That Has Progressed Or Recurred After Prior Fluropyrimidine-Based Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2016
Price :
$35
*
At a glance
- Drugs Edotecarin (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 16 Nov 2006 Status change
- 16 Nov 2006 The expected completion date for this trial is now .
- 07 Sep 2005 New trial record.